Symbols / SNSE $30.01 +0.37%
SNSE Chart
About
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 37.86M |
| Enterprise Value | 14.83M | Income | -24.14M | Sales | — |
| Book/sh | 18.24 | Cash/sh | 19.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -26.79 | PEG | — |
| P/S | — | P/B | 1.65 | P/C | — |
| EV/EBITDA | -0.63 | EV/Sales | — | Quick Ratio | 5.64 |
| Current Ratio | 5.81 | Debt/Eq | 8.78 | LT Debt/Eq | — |
| EPS (ttm) | -19.14 | EPS next Y | -1.12 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 07:00 | ROA | -37.04% |
| ROE | -70.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.26M |
| Shs Float | 733.60K | Short Float | 63.52% | Short Ratio | 0.81 |
| Short Interest | — | 52W High | 36.76 | 52W Low | 5.00 |
| Beta | -0.08 | Avg Volume | 322.20K | Volume | 57.61K |
| Target Price | — | Recom | None | Prev Close | $29.90 |
| Price | $30.01 | Change | 0.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$30.01
Latest analyst target
3. DCF / Fair value
$-189.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-30 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-08-05 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-28 | main | Oppenheimer | Outperform → Outperform | $4 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-07 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-24 | reit | Stephens & Co. | Overweight → Overweight | $5 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $5 |
| 2023-12-04 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2022-12-13 | init | Citigroup | — → Buy | $6 |
| 2022-10-03 | up | Oppenheimer | Perform → Outperform | $5 |
| 2022-03-10 | main | Piper Sandler | — → Overweight | $10 |
| 2021-07-01 | down | Berenberg | Buy → Hold | $12 |
| 2021-06-29 | down | Oppenheimer | Outperform → Perform | — |
| 2021-03-01 | init | Oppenheimer | — → Outperform | $36 |
| 2021-03-01 | init | Piper Sandler | — → Overweight | $25 |
- $SNSE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 19
- Sensei Biotherapeutics (SNSE) Announces Stock Option Grant to Ne - GuruFocus ue, 17 Mar 2026 15
- How The Compañía Cervecerías Unidas (SNSE:CCU) Story Is Shifting With New Targets And Assumptions - Yahoo Finance ue, 17 Mar 2026 07
- (SNSE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Sun, 15 Mar 2026 20
- Sensei Biotherapeutics stock soars after Faeth Therapeutics acquisition - Investing.com Wed, 18 Feb 2026 08
- Sensei Biotherapeutics hands new COO 1.24M stock options - Stock Titan Wed, 25 Feb 2026 08
- SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits Wed, 18 Feb 2026 17
- SNSE: Stock-for-stock acquisition and $200M financing accelerate clinical development of novel cancer therapies - TradingView Wed, 18 Feb 2026 08
- What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump? - Benzinga Fri, 05 Dec 2025 08
- SNSE - Sensei Biotherapeutics, Inc. Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 17
- How The New Price Target Is Shaping The Banco Santander-Chile (SNSE:BSANTANDER) Story - Yahoo Finance hu, 22 Jan 2026 08
- Sensei Biotherapeutics (NASDAQ: SNSE) discontinues solnerstotug, begins strategic review - Stock Titan hu, 30 Oct 2025 07
- How The Investment Story For Banco Santander Chile (SNSE:BSANTANDER) Is Quietly Shifting - Yahoo Finance Sun, 08 Mar 2026 08
- Sensei Biotherapeutics Reports 6‑Mo PFS 50% at 15 mg/kg | SNSE Stock News - Stock Titan Fri, 17 Oct 2025 07
- $SNSE stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 23 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6612 | 54575 | — | Sale at price 7.92 - 8.59 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | I |
| 1 | 6612 | 54575 | — | Sale at price 7.92 - 8.59 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | D |
| 2 | 395 | 2528 | — | Conversion of Exercise of derivative security at price 6.40 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | I |
| 3 | 395 | 2528 | — | Conversion of Exercise of derivative security at price 6.40 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | D |
| 4 | 21295 | 228061 | — | Sale at price 9.06 - 11.40 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-05 00:00:00 | I |
| 5 | 21295 | 228061 | — | Sale at price 9.06 - 11.40 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -27.79M | -32.30M | -47.02M | -36.01M |
| TotalUnusualItems | -951.00K | -302.00K | 0.00 | 567.00K |
| TotalUnusualItemsExcludingGoodwill | -951.00K | -302.00K | 0.00 | 567.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.16M | -34.10M | -48.59M | -36.79M |
| ReconciledDepreciation | 1.32M | 1.35M | 1.35M | 685.00K |
| EBITDA | -28.75M | -32.61M | -47.02M | -35.44M |
| EBIT | -30.07M | -33.96M | -48.37M | -36.12M |
| NetInterestIncome | 2.46M | 3.48M | 1.56M | 130.00K |
| InterestExpense | 90.00K | 144.00K | 219.00K | 670.00K |
| InterestIncome | 2.55M | 3.62M | 1.78M | 800.00K |
| NormalizedIncome | -29.21M | -33.80M | -48.59M | -37.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.16M | -34.10M | -48.59M | -36.79M |
| TotalExpenses | 31.66M | 37.06M | 50.19M | 37.48M |
| TotalOperatingIncomeAsReported | -32.61M | -37.06M | -50.19M | -37.48M |
| DilutedAverageShares | 1.26M | 1.40M | 1.54M | 1.39M |
| BasicAverageShares | 1.26M | 1.40M | 1.54M | 1.39M |
| DilutedEPS | -24.00 | -24.40 | -31.60 | -26.60 |
| BasicEPS | -24.00 | -24.40 | -31.60 | -26.60 |
| DilutedNIAvailtoComStockholders | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeCommonStockholders | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncome | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeIncludingNoncontrollingInterests | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeContinuousOperations | -30.16M | -34.10M | -48.59M | -36.79M |
| PretaxIncome | -30.16M | -34.10M | -48.59M | -36.79M |
| OtherIncomeExpense | -954.00K | -517.00K | 36.00K | 558.00K |
| OtherNonOperatingIncomeExpenses | -3.00K | -215.00K | 36.00K | -9.00K |
| SpecialIncomeCharges | -951.00K | -302.00K | 0.00 | 567.00K |
| GainOnSaleOfPPE | 0.00 | -302.00K | 0.00 | -9.00K |
| OtherSpecialCharges | -567.00K | |||
| ImpairmentOfCapitalAssets | 951.00K | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 2.46M | 3.48M | 1.56M | 130.00K |
| InterestExpenseNonOperating | 90.00K | 144.00K | 219.00K | 670.00K |
| InterestIncomeNonOperating | 2.55M | 3.62M | 1.78M | 800.00K |
| OperatingIncome | -31.66M | -37.06M | -50.19M | -37.48M |
| OperatingExpense | 31.66M | 37.06M | 50.19M | 37.48M |
| ResearchAndDevelopment | 18.63M | 18.30M | 30.38M | 21.66M |
| SellingGeneralAndAdministration | 13.04M | 18.77M | 19.80M | 15.82M |
| GeneralAndAdministrativeExpense | 13.04M | 18.77M | 19.80M | 15.82M |
| OtherGandA | 13.04M | 18.77M | 19.80M | 15.82M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.26M | 1.25M | 1.54M | 1.53M |
| ShareIssued | 1.26M | 1.25M | 1.54M | 1.53M |
| TotalDebt | 3.85M | 6.21M | 8.03M | 2.35M |
| TangibleBookValue | 38.39M | 64.89M | 103.41M | 146.51M |
| InvestedCapital | 38.39M | 64.89M | 103.41M | 146.51M |
| WorkingCapital | 36.48M | 61.61M | 99.52M | 143.65M |
| NetTangibleAssets | 38.39M | 64.89M | 103.41M | 146.51M |
| CapitalLeaseObligations | 3.85M | 6.21M | 8.03M | 2.35M |
| CommonStockEquity | 38.39M | 64.89M | 103.41M | 146.51M |
| TotalCapitalization | 38.39M | 64.89M | 103.41M | 146.51M |
| TotalEquityGrossMinorityInterest | 38.39M | 64.89M | 103.41M | 146.51M |
| StockholdersEquity | 38.39M | 64.89M | 103.41M | 146.51M |
| GainsLossesNotAffectingRetainedEarnings | -13.00K | -209.00K | -1.00M | -333.00K |
| OtherEquityAdjustments | -13.00K | -209.00K | -1.00M | -333.00K |
| RetainedEarnings | -262.05M | -231.90M | -197.79M | -149.21M |
| AdditionalPaidInCapital | 300.45M | 297.00M | 302.20M | 296.05M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 6.97M | 9.48M | 14.97M | 6.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.53M | 3.84M | 5.90M | 1.82M |
| OtherNonCurrentLiabilities | 67.00K | 149.00K | ||
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.53M | 3.77M | 5.90M | 1.67M |
| LongTermCapitalLeaseObligation | 1.53M | 3.77M | 5.90M | 1.67M |
| CurrentLiabilities | 5.45M | 5.64M | 9.07M | 4.89M |
| CurrentDebtAndCapitalLeaseObligation | 2.32M | 2.44M | 2.13M | 680.00K |
| CurrentCapitalLeaseObligation | 2.32M | 2.44M | 2.13M | 680.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.88M | 1.51M | 2.46M | 1.75M |
| PayablesAndAccruedExpenses | 1.25M | 1.69M | 4.47M | 2.46M |
| Payables | 2.46M | |||
| AccountsPayable | 2.46M | |||
| TotalAssets | 45.36M | 74.37M | 118.38M | 153.22M |
| TotalNonCurrentAssets | 3.43M | 7.12M | 9.79M | 4.68M |
| OtherNonCurrentAssets | 48.00K | 86.00K | 63.00K | 39.00K |
| NetPPE | 3.38M | 7.04M | 9.72M | 4.64M |
| AccumulatedDepreciation | -1.50M | -1.73M | -1.44M | -1.19M |
| GrossPPE | 4.88M | 8.77M | 11.17M | 5.83M |
| Leases | 253.00K | 253.00K | 253.00K | 253.00K |
| OtherProperties | 4.27M | 7.98M | 10.38M | 4.97M |
| MachineryFurnitureEquipment | 354.00K | 532.00K | 532.00K | 606.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.93M | 67.25M | 108.59M | 148.54M |
| OtherCurrentAssets | 120.00K | 325.00K | 344.00K | 374.00K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 474.00K | 1.17M | 1.13M | 547.00K |
| CashCashEquivalentsAndShortTermInvestments | 41.34M | 65.76M | 107.12M | 147.62M |
| OtherShortTermInvestments | 31.34M | 52.75M | 89.32M | 140.46M |
| CashAndCashEquivalents | 9.99M | 13.01M | 17.80M | 7.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.82M | -32.20M | -39.35M | -32.28M |
| RepurchaseOfCapitalStock | 0.00 | -10.38M | 0.00 | |
| RepaymentOfDebt | -811.00K | -761.00K | -629.00K | -255.00K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 164.09M | ||
| CapitalExpenditure | -146.00K | -180.00K | -321.00K | -2.03M |
| InterestPaidSupplementalData | 0.00 | 57.00K | ||
| EndCashPosition | 9.99M | 13.01M | 17.80M | 7.16M |
| BeginningCashPosition | 13.01M | 17.80M | 7.16M | 16.60M |
| ChangesInCash | -3.02M | -4.78M | 10.64M | -9.44M |
| FinancingCashFlow | -787.00K | -11.17M | -287.00K | 163.94M |
| CashFlowFromContinuingFinancingActivities | -787.00K | -11.17M | -287.00K | 163.94M |
| NetOtherFinancingCharges | -10.00K | -76.00K | ||
| ProceedsFromStockOptionExercised | 34.00K | 48.00K | 342.00K | 109.00K |
| NetPreferredStockIssuance | 0.00 | 23.49M | ||
| PreferredStockIssuance | 0.00 | 23.49M | ||
| NetCommonStockIssuance | 0.00 | -10.38M | 0.00 | 140.59M |
| CommonStockPayments | 0.00 | -10.38M | 0.00 | |
| CommonStockIssuance | 0.00 | 140.59M | ||
| NetIssuancePaymentsOfDebt | -811.00K | -761.00K | -629.00K | -255.00K |
| NetLongTermDebtIssuance | -811.00K | -761.00K | -629.00K | -255.00K |
| LongTermDebtPayments | -811.00K | -761.00K | -629.00K | -255.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 22.44M | 38.41M | 49.95M | -143.12M |
| CashFlowFromContinuingInvestingActivities | 22.44M | 38.41M | 49.95M | -143.12M |
| NetInvestmentPurchaseAndSale | 22.59M | 38.43M | 50.26M | -141.41M |
| SaleOfInvestment | 67.18M | 59.58M | 97.12M | 42.26M |
| PurchaseOfInvestment | -44.59M | -21.15M | -46.87M | -183.67M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -146.00K | -14.00K | -306.00K | -1.71M |
| SaleOfPPE | 0.00 | 166.00K | 15.00K | 318.00K |
| PurchaseOfPPE | -146.00K | -180.00K | -321.00K | -2.03M |
| OperatingCashFlow | -24.67M | -32.02M | -39.03M | -30.26M |
| CashFlowFromContinuingOperatingActivities | -24.67M | -32.02M | -39.03M | -30.26M |
| ChangeInWorkingCapital | -489.00K | -4.33M | 1.01M | 117.00K |
| ChangeInOtherWorkingCapital | 666.00K | -650.00K | 709.00K | 837.00K |
| ChangeInOtherCurrentLiabilities | -1.65M | -1.27M | -1.14M | 205.00K |
| ChangeInOtherCurrentAssets | 244.00K | 22.00K | 5.00K | -327.00K |
| ChangeInPayablesAndAccruedExpense | -445.00K | -2.33M | 2.02M | -1.43M |
| ChangeInAccruedExpense | 0.00 | |||
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | -1.43M | |||
| ChangeInAccountPayable | -1.43M | |||
| ChangeInPrepaidAssets | 694.00K | -99.00K | -582.00K | 828.00K |
| OtherNonCashItems | 1.55M | 1.36M | 1.19M | 57.00K |
| StockBasedCompensation | 3.13M | 4.45M | 5.81M | 5.66M |
| AssetImpairmentCharge | 951.00K | 0.00 | ||
| AmortizationOfSecurities | -986.00K | -1.06M | 231.00K | 615.00K |
| DepreciationAmortizationDepletion | 1.32M | 1.35M | 1.35M | 685.00K |
| DepreciationAndAmortization | 1.32M | 1.35M | 1.35M | 685.00K |
| Depreciation | 1.32M | 1.35M | 1.35M | 685.00K |
| OperatingGainsLosses | 302.00K | -30.00K | -596.00K | |
| GainLossOnInvestmentSecurities | -15.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 302.00K | -15.00K | -29.00K |
| NetIncomeFromContinuingOperations | -30.16M | -34.10M | -48.59M | -36.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNSE
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|